Combined effects of goserelin and tamoxifen on estradiol level, breast density, and endometrial thickness in premenopausal and perimenopausal women with early-stage hormone receptor-positive breast cancer: a randomised controlled clinical trial

Buzdar A(2006)Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial Lancet Oncol 7 633-643

Howell A(2006)Adjuvant goserelin in pre-menopausal patients with early breast cancer: results from the ZIPP study Eur J Cancer 42 895-904

Cuzick J(2009)Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer N Engl J Med 361 766-776

Wale C(2005)A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer N Engl J Med 353 2747-2757

Distler W(2005)Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women Drugs 65 2639-2655

Hoctin-Boes G(2008)WITHDRAWN: tamoxifen for early breast cancer Cochrane Database Syst Rev 8 CD000486-492

Houghton J(2007)Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98 J Clin Oncol 25 486-1124

Locker GY(2011)Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 Study J Clin Oncol 29 1117-1092

Nabholtz JM(2004)A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 1081-1723

Baum M(2007)Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials Lancet 369 1711-752

Buzdar A(2006)Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial Lancet Oncol 7 633-643

Howell A(2006)Adjuvant goserelin in pre-menopausal patients with early breast cancer: results from the ZIPP study Eur J Cancer 42 895-904

Cuzick J(2009)Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer N Engl J Med 361 766-776

Wale C(2005)A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer N Engl J Med 353 2747-2757

Distler W(2005)Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women Drugs 65 2639-2655

Hoctin-Boes G(2008)WITHDRAWN: tamoxifen for early breast cancer Cochrane Database Syst Rev 8 CD000486-492

Houghton J(2007)Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98 J Clin Oncol 25 486-1124

Locker GY(2011)Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 Study J Clin Oncol 29 1117-1092

Nabholtz JM(2004)A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 1081-1723

Baum M(2007)Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials Lancet 369 1711-752